Sarasota, FL (PRWEB) July 30, 2014 -- Rapid Pathogen Screening, Inc. (RPS®), an emerging leader in point-of-care (POC) diagnostic testing, today announced that Peter Grady has joined RPS as Chief Financial Officer (CFO). Mr. Grady has more than 20 years of financial management experience across a variety of manufacturing companies with worldwide operations. Prior to joining RPS, he was the finance leader of Becton Dickinson’s Biosciences business unit, which develops, manufactures, markets, and sells diagnostic tests for HIV and cancer.
“Pete is a senior finance executive and dynamic business leader with a strong track record in the life sciences industry at both early-stage and multinational companies. He is the ideal financial leader to drive growth and add shareholder value,” said Robert Sambursky, MD, chief executive officer and president of RPS. “In his previous roles, Pete has proven to be a key member of executive management teams – driving financial planning and analysis, mergers and acquisitions, strategic deal-making, operational effectiveness, and business development. His extensive, on-point experience will provide critical support for the advancement of our commercial product portfolio.”
Grady has facilitated the success of both private and public organizations ranging in size from $20 million to more than $1 billion in revenue. His extensive global business experience was strengthened during his work as an expatriate in Switzerland while integrating the acquisition of a Swiss company. Grady earned his MBA from the University of San Diego and his BS from the University of the Pacific.
“In addition to overseeing financial operations, I look forward to joining Dr. Sambursky, RPS’s versatile and passionate founder and chief executive officer, in working to help the company achieve its full potential,” said Grady. “I am thrilled to be a part of RPS’s continued positive impact on global healthcare.”
Founded in 2004, Rapid Pathogen Screening, Inc. (RPS) is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to support the rapid diagnosis of patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being developed to help detect the body’s immune response to viral and bacterial infections as well as chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment. Currently available RPS tests include AdenoPlus® to aid in the diagnosis of Adenoviral conjunctivitis (pink eye) and InflammaDry® to aid in the diagnosis of dry eye disease. For more information on RPS or its products, visit RPSdetectors.com.
# # #
Media contact: Laura Lovejoy • laura(at)saranova(dot)net • 941.928.9025
Laura Lovejoy, Rapid Pathogen Screening, Inc. (RPS), http://www.rpsdetectors.com, +1 (941) 928-9025, [email protected]
SOURCE Rapid Pathogen Screening, Inc. (RPS)